Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

New promising anticancer agents in development: what comes next?

¹Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), The Netherlands.

Cancer Chemotherapy and Pharmacology

|January 1, 1996

Summary

Innovative anticancer drugs are emerging, targeting cancer cell growth mechanisms. New agents like gemcitabine and irinotecan show promise in treating various cancers, with ongoing research into novel therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Innovation in oncology clinical trial design.

Cancer treatment reviews·2019

Same author

Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.

Hematology (Amsterdam, Netherlands)·2016

Same author

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

European journal of cancer (Oxford, England : 1990)·2015

Same author

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.

Cancer chemotherapy and pharmacology·2014

Same author

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

Same author

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.

European journal of cancer (Oxford, England : 1990)·2014

Area of Science:

Oncology
Pharmacology
Drug Development

Background:

Anticancer drug development is shifting towards innovative agents.
Increased understanding of cancer pathogenetic mechanisms enables mechanism-based drug screening.
New therapeutic targets are being identified for anticancer drug treatment.

Purpose of the Study:

To review recent advancements in innovative anticancer drug development.
To highlight novel anticancer agents and their mechanisms of action.
To discuss emerging therapeutic strategies in oncology.

Main Methods:

Review of current literature on novel anticancer agents.
Discussion of drugs in clinical studies and advanced development.
Analysis of mechanism-based drug screening and new targets.

Related Experiment Videos

Main Results:

New agents like carzelesin and oral platins (e.g., JM216) are in clinical studies.
Gemcitabine shows activity in non-small-cell lung cancer; Tomudex in colorectal cancer.
Topoisomerase I inhibitors (irinotecan, topotecan) demonstrate efficacy in various cancers.
Protein kinase C inhibitors and immunoconjugates of doxorubicin are under development.

Conclusions:

Mechanism-based drug development is yielding promising new anticancer agents.
Several novel drugs targeting specific cancer pathways are advancing through clinical trials.
Future anticancer strategies may involve targeted therapies and innovative drug delivery systems.